Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Allogene
Biotech
Allogene reports patient death tied to mAb in CAR-T pivotal trial
Given the patient death, the company is dropping the monoclonal antibody called ALLO-647 completely, CEO David Chang told Fierce.
Gabrielle Masson
Aug 1, 2025 8:30am
Allogene lays off 28% of staff to save cash amid program delays
May 14, 2025 8:00am
Allogene’s lymphoma data show CAR-T could ‘leapfrog’ competition
Feb 14, 2025 10:35am
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Nov 14, 2024 5:59am
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Nov 8, 2024 4:47am
How to get cell therapies flying off-the-shelf
May 31, 2024 9:00am
